CMC

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

Retrieved on: 
Wednesday, January 3, 2024

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and will host a corporate webinar at 8:30 am ET.

Key Points: 
  • “2023 was a very productive year for SELLAS,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.
  • Dr. Stergiou continued: “We hope to build on this excellent progress and look forward to multiple clinical milestones that have the potential to create significant value for our shareholders.
  • Meaningful cell killing activity, defined as ≥50% reduction in blasts in the bone marrow, was observed at several dose levels.
  • This study is fully funded by the Company’s partner for SLS009, GenFleet Therapeutics (Shanghai), Inc. and is being conducted in China.

WuXi XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development

Retrieved on: 
Wednesday, January 3, 2024

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel Camptothecin drugs called NexatecansTM, a new class of OHPAS-able Camptothecins.

Key Points: 
  • Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel Camptothecin drugs called NexatecansTM, a new class of OHPAS-able Camptothecins.
  • WuXi XDC will provide fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services.
  • This synergy will empower clients of both parties to accelerate PCC (Pre-clinical candidates) selection further, develop more next-generation ADCs and other bioconjugates, and expedite the CMC development process.
  • It demonstrates WuXi XDC's platform development strategy, namely to grow continually and evolve to help our clients to accelerate and transform the discovery, development and manufacturing of ADCs and other bioconjugates. "

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – OTLK

Retrieved on: 
Tuesday, January 2, 2024

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) and certain officers.

Key Points: 
  • NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

OTLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, January 2, 2024

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/otlk .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/otlk .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

OTLK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Retrieved on: 
Saturday, December 30, 2023

WHAT TO DO NEXT: To join the Outlook class action, go to https://rosenlegal.com/submit-form/?case_id=20224 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Outlook class action, go to https://rosenlegal.com/submit-form/?case_id=20224 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program

Retrieved on: 
Friday, December 29, 2023

NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood and solid cancers, today announced an agreement with Miltenyi to develop and manufacture its expanded hematopoietic stem cell transplantation (HSCT) product for clinical use in hematology-oncology.

Key Points: 
  • NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood and solid cancers, today announced an agreement with Miltenyi to develop and manufacture its expanded hematopoietic stem cell transplantation (HSCT) product for clinical use in hematology-oncology.
  • Cell BioEngines’ proprietary stem cell expansion technology provides an ‘off-the-shelf’ curative treatment for blood cancer patients who need a bone marrow transplant.
  • Under the terms of the agreement, Miltenyi will begin development leading towards Good Manufacturing Practices (GMP) manufacturing of the Phase 1 clinical trial batches of Cell BioEngines’ CBE-101 clinical program.
  • "Working with Miltenyi enables us to avoid the need to invest time, resources and capital in constructing our own CMC development and manufacturing capabilities.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Retrieved on: 
Saturday, December 2, 2023

WHAT TO DO NEXT: To join the Outlook class action, go to https://rosenlegal.com/submit-form/?case_id=20224 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Outlook class action, go to https://rosenlegal.com/submit-form/?case_id=20224 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

AXSM FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

Retrieved on: 
Friday, November 24, 2023

WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, A LEADING LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Retrieved on: 
Monday, November 20, 2023

WHAT TO DO NEXT: To join the Outlook class action, go to https://rosenlegal.com/submit-form/?case_id=20224 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Outlook class action, go to https://rosenlegal.com/submit-form/?case_id=20224 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

NATIONALLY RANKED ROSEN LAW FIRM Encourages Outlook Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Retrieved on: 
Tuesday, November 14, 2023

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.

Key Points: 
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.